Phase 2 Trial Updates on Sotatercept in Treating PAH Set for ATS 2021

Phase 2 Trial Updates on Sotatercept in Treating PAH Set for ATS 2021

291329

Phase 2 Trial Updates on Sotatercept in Treating PAH Set for ATS 2021

Treatment with Acceleron Pharma’s sotatercept appears to be effective and generally well tolerated in people with pulmonary arterial hypertension (PAH), according to new data from the ongoing PULSAR and SPECTRA Phase 2 clinical trials. These data will be presented at the American Thoracic Society (ATS) 2021 International Conference to be held virtually on May 14–19. “It’s quite gratifying to return to the ATS International Conference with new sotatercept data, having first presented topline results from…

You must be logged in to read/download the full post.